Xeris Biopharma Holdings Financials
Xeris Biopharma Holdings (XERS) reported $291.8M in revenue for fiscal year 2025, up 43.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Scale-driven gross profit expansion finally covered commercial and research overhead, but debt service still restrains what reaches shareholders.
From FY2023 to FY2025, gross profit rose by$114M while SG&A plus R&D increased only$45.1M , showing that the move toward profitability came mainly from fixed-cost absorption rather than a dramatic cut in spending. That operating leverage turned operating cash flow from-$47.0M to$28.6M , so the improvement is showing up in cash and not only in accounting earnings.
FY2025's operating profit of
Day-to-day liquidity looks better than the small equity cushion suggests: cash reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Xeris Biopharma Holdings's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Xeris Biopharma Holdings has an operating margin of 8.5%, meaning the company retains $9 of operating profit per $100 of revenue. This below-average margin results in a low score of 27/100, suggesting thin profitability after operating expenses. This is up from -16.6% the prior year.
Xeris Biopharma Holdings's revenue surged 43.7% year-over-year to $291.8M, reflecting rapid business expansion. This strong growth earns a score of 91/100.
Xeris Biopharma Holdings has elevated debt relative to equity (D/E of 16.10), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 14/100, reflecting increased financial risk.
Xeris Biopharma Holdings's current ratio of 2.19 indicates adequate short-term liquidity, earning a score of 62/100. The company can meet its near-term obligations, though with limited headroom.
Not available for Xeris Biopharma Holdings, and counted as zero in the overall score.
Xeris Biopharma Holdings's ROE of 4.0% shows moderate profitability relative to equity, earning a score of 30/100.
Xeris Biopharma Holdings scores 1.51, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.6B) relative to total liabilities ($369.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Xeris Biopharma Holdings passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Xeris Biopharma Holdings reported $554K of net income while generating $28.6M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.
Xeris Biopharma Holdings earns $0.86 in operating income for every $1 of interest expense ($24.9M vs $29.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Xeris Biopharma Holdings generated $291.8M in revenue in fiscal year 2025. This represents an increase of 43.7% from the prior year.
Xeris Biopharma Holdings's EBITDA was $26.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 180.8% from the prior year.
Xeris Biopharma Holdings reported $554K in net income in fiscal year 2025. This represents an increase of 101.0% from the prior year.
Xeris Biopharma Holdings earned $0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.0% from the prior year.
Cash & Balance Sheet
Xeris Biopharma Holdings held $111.0M in cash against $220.3M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Xeris Biopharma Holdings's gross margin was 85.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.5 percentage points from the prior year.
Xeris Biopharma Holdings's operating margin was 8.5% in fiscal year 2025, reflecting core business profitability. This is up 25.1 percentage points from the prior year.
Xeris Biopharma Holdings's net profit margin was 0.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 27.2 percentage points from the prior year.
Xeris Biopharma Holdings's ROE was 4.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Xeris Biopharma Holdings invested $31.2M in research and development in fiscal year 2025. This represents an increase of 21.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
XERS Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | $335.4M | $291.8M+43.7% | $203.1M+23.9% | $163.9M+48.7% | $110.2M+122.3% | $49.6M+142.7% | $20.4M |
| Cost of Revenue | $45.0M | $42.6M+15.6% | $36.8M+28.6% | $28.6M+26.6% | $22.6M+70.0% | $13.3M+42.8% | $9.3M |
| Gross Profit | $290.4M | $249.3M+50.0% | $166.2M+22.9% | $135.3M+54.4% | $87.6M+141.5% | $36.3M+226.6% | $11.1M |
| R&D Expenses | $34.8M | $31.2M+21.9% | $25.6M+14.4% | $22.3M+6.6% | $21.0M-16.7% | $25.2M+20.3% | $20.9M |
| SG&A Expenses | $208.1M | $182.4M+11.6% | $163.5M+11.9% | $146.1M+6.1% | $137.7M+9.6% | $125.7M+70.5% | $73.7M |
| Operating Income | $36.6M | $24.9M+174.0% | -$33.6M+23.5% | -$44.0M+46.3% | -$81.9M+28.8% | -$115.2M-37.8% | -$83.5M |
| Interest Expense | $28.3M | $29.1M-4.6% | $30.5M+14.6% | $26.6M+88.7% | $14.1M+96.4% | $7.2M-32.6% | $10.7M |
| Income Tax | $0 | $0+100.0% | -$2.3M-81.6% | -$1.2M+12.3% | -$1.4M | $0+100.0% | -$110K |
| Net Income | -$17.2M | $554K+101.0% | -$54.8M+11.9% | -$62.3M+34.2% | -$94.7M+22.9% | -$122.7M-34.7% | -$91.1M |
| EPS (Diluted) | — | $0.00+100.0% | -$0.37+17.8% | -$0.45+35.7% | -$0.70 | -$1.55 | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
XERS Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $383.5M+18.7% | $323.1M+0.1% | $322.6M-6.4% | $344.5M+13.2% | $304.4M+91.2% | $159.2M |
| Current Assets | $240.3M+43.3% | $167.7M+7.3% | $156.3M-16.4% | $186.8M+31.0% | $142.6M-6.3% | $152.2M |
| Cash & Equivalents | $111.0M+55.0% | $71.6M+6.2% | $67.4M-44.7% | $122.0M+81.3% | $67.3M+78.9% | $37.6M |
| Inventory | $68.7M+42.5% | $48.2M+24.0% | $38.8M+57.0% | $24.7M+36.5% | $18.1M+116.9% | $8.4M |
| Accounts Receivable | $51.0M+26.3% | $40.4M+3.1% | $39.2M+27.1% | $30.8M+76.6% | $17.5M+153.9% | $6.9M |
| Goodwill | $22.9M0.0% | $22.9M0.0% | $22.9M0.0% | $22.9M0.0% | $22.9M | $0 |
| Total Liabilities | $369.8M+4.9% | $352.7M+7.1% | $329.4M+10.0% | $299.3M+43.1% | $209.1M+66.8% | $125.4M |
| Current Liabilities | $109.6M+9.1% | $100.4M+5.5% | $95.2M+29.3% | $73.6M-6.9% | $79.0M+180.2% | $28.2M |
| Long-Term Debt | $220.3M+1.5% | $217.0M+13.7% | $190.9M+2.1% | $187.1M+112.4% | $88.1M+1.2% | $87.0M |
| Total Equity | $13.7M+146.2% | -$29.6M-336.7% | -$6.8M-115.0% | $45.2M-52.6% | $95.2M+182.1% | $33.8M |
| Retained Earnings | -$671.3M+0.1% | -$671.9M-8.9% | -$617.0M-11.2% | -$554.8M-20.6% | -$460.1M-36.4% | -$337.4M |
XERS Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $56.6M | $28.6M+177.4% | -$37.0M+21.4% | -$47.0M+54.3% | -$102.9M-7.7% | -$95.5M-18.6% | -$80.6M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $1.1M+187.8% | $377K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$96.6M-19.4% | -$80.9M |
| Investing Cash Flow | -$938K | -$696K-114.3% | $4.9M+181.3% | -$6.0M-117.4% | $34.5M-64.8% | $98.0M+457.5% | -$27.4M |
| Financing Cash Flow | $6.7M | $11.4M-68.5% | $36.2M+2342.3% | -$1.6M-101.3% | $127.5M+367.8% | $27.2M-78.4% | $126.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
XERS Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Gross Margin | 85.4%+3.5pp | 81.9%-0.7pp | 82.5%+3.1pp | 79.5%+6.3pp | 73.1%+18.8pp | 54.4% |
| Operating Margin | 8.5%+25.1pp | -16.6%+10.3pp | -26.9%+47.5pp | -74.3% | -232.2% | -408.8% |
| Net Margin | 0.2%+27.2pp | -27.0%+11.0pp | -38.0%+47.9pp | -85.9% | -247.5% | -446.0% |
| Return on Equity | 4.0% | N/A | N/A | -209.5%-80.6pp | -128.9%+141.1pp | -270.0% |
| Return on Assets | 0.1%+17.1pp | -17.0%+2.3pp | -19.3%+8.2pp | -27.5%+12.8pp | -40.3%+16.9pp | -57.3% |
| Current Ratio | 2.19+0.5x | 1.670.0x | 1.64-0.9x | 2.54+0.7x | 1.80-3.6x | 5.40 |
| Debt-to-Equity | 16.10 | N/A | N/A | 4.14+3.2x | 0.92-1.7x | 2.58 |
| FCF Margin | N/A | N/A | N/A | N/A | -194.8% | -396.1% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Xeris Biopharma Holdings Ranks
Frequently Asked Questions
What is Xeris Biopharma Holdings's annual revenue?
Xeris Biopharma Holdings (XERS) reported $291.8M in total revenue for fiscal year 2025. This represents a 43.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Xeris Biopharma Holdings's revenue growing?
Xeris Biopharma Holdings (XERS) revenue grew by 43.7% year-over-year, from $203.1M to $291.8M in fiscal year 2025.
Is Xeris Biopharma Holdings profitable?
Yes, Xeris Biopharma Holdings (XERS) reported a net income of $554K in fiscal year 2025, with a net profit margin of 0.2%.
What is Xeris Biopharma Holdings's EBITDA?
Xeris Biopharma Holdings (XERS) had EBITDA of $26.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Xeris Biopharma Holdings have?
As of fiscal year 2025, Xeris Biopharma Holdings (XERS) had $111.0M in cash and equivalents against $220.3M in long-term debt.
What is Xeris Biopharma Holdings's gross margin?
Xeris Biopharma Holdings (XERS) had a gross margin of 85.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Xeris Biopharma Holdings's operating margin?
Xeris Biopharma Holdings (XERS) had an operating margin of 8.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Xeris Biopharma Holdings's net profit margin?
Xeris Biopharma Holdings (XERS) had a net profit margin of 0.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Xeris Biopharma Holdings's return on equity (ROE)?
Xeris Biopharma Holdings (XERS) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Xeris Biopharma Holdings's operating cash flow?
Xeris Biopharma Holdings (XERS) generated $28.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Xeris Biopharma Holdings's total assets?
Xeris Biopharma Holdings (XERS) had $383.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Xeris Biopharma Holdings spend on research and development?
Xeris Biopharma Holdings (XERS) invested $31.2M in research and development during fiscal year 2025.
What is Xeris Biopharma Holdings's current ratio?
Xeris Biopharma Holdings (XERS) had a current ratio of 2.19 as of fiscal year 2025, which is generally considered healthy.
What is Xeris Biopharma Holdings's debt-to-equity ratio?
Xeris Biopharma Holdings (XERS) had a debt-to-equity ratio of 16.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Xeris Biopharma Holdings's return on assets (ROA)?
Xeris Biopharma Holdings (XERS) had a return on assets of 0.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Xeris Biopharma Holdings's Altman Z-Score?
Xeris Biopharma Holdings (XERS) has an Altman Z-Score of 1.51, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Xeris Biopharma Holdings's Piotroski F-Score?
Xeris Biopharma Holdings (XERS) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Xeris Biopharma Holdings's earnings high quality?
Xeris Biopharma Holdings (XERS) reported $554K of net income while generating $28.6M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Xeris Biopharma Holdings cover its interest payments?
Xeris Biopharma Holdings (XERS) has an interest coverage ratio of 0.86x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Xeris Biopharma Holdings?
Xeris Biopharma Holdings (XERS) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.